Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent Pfizer-BioNTech COVID-19 vaccine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The bivalent Pfizer-BioNTech COVID-19 vaccine is a second-generation mRNA vaccine developed to broaden protection against SARS-CoV-2 by targeting both the original ancestral strain and the Omicron variant. It contains two mRNA components (tozinameran and famtozinameran) encapsulated in lipid nanoparticles, each encoding the viral spike protein. This specific formulation, often referred to as Comirnaty Original/Omicron BA.1, was evaluated in a Phase 3 clinical trial sponsored by the Murdoch Childrens Research Institute to assess its safety and immunogenicity as a second booster dose in healthy adults. The vaccine works by inducing the host's cells to produce spike proteins, thereby stimulating a robust immune response including the production of neutralizing antibodies and activation of T-cells.
- Brand names
- Comirnaty Original/Omicron BA.1
- Other names
- Bivalent Pfizer-BioNTech COVID-19 VaccineTozinameran + Famtozinameran
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on bivalent Pfizer-BioNTech COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent Pfizer-BioNTech COVID-19 vaccine.